A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer

Gastrointestinal Cancer Research

Volumn 5, Issue 5, 2012, Pages 155-160

  Rocha Lima, Caio M ^a   Lin, Edward H ^b   Kim, George P ^c   Giguere, Jeffrey K ^d   Marshall, John ^e   Zalupski, Mark ^f   Papageorgio, Chris ^g   Auber, Miklos L ^h   Kaleta, Remigiusz ⁱ   Mchenry, M Brent ⁱ   Trifan, Ovidiu C ⁱ   Philip, Philip A ^j  

^a UNIVERSITY OF MIAMI   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c MAYO CLINIC   (United States)

^d Cancer Centers of the Carolinas Seneca   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF MISSOURI   (United States)

^h WEST VIRGINIA UNIVERSITY   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IXABEPILONE;

ACNE; ACNE FORM DERMATITIS; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84873449753     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, et al: Cancer Statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology™: pancreatic adenocarcinoma. V2. 2010. Available at: www.nccn.org. Accessed February 4, 2011
3. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413, 1997
4. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
5. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952, 2006
6. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007
7. Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778-3785, 2009
8. Conroy T, Desseigne F, Ychou M, et al: Ran- domized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and ox- aliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28(suppl 15):303s, 2010 (abstr 4010)
9. Rivera E, Lee J, Davies A: Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 13: 1207-1223, 2008
10. Lee FY, Borzilleri R, Fairchild CR, et al: PreClinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 63:157-166, 2008
11. Lee FY, Smykla R, Johnston K, et al: Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 63: 201-212, 2009
12. Whitehead RP, McCoy S, Rivkin SE, et al: A phase II trial of epothilone B analogue BMS- 247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24: 515-520, 2006
13. Overholser JP, Prewett MC, Hooper AT, et al: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74-82, 2000
14. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22:2610-2616, 2004
15. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28;3605-3610, 2010
16. Lee F, Jure-Kunkel MN, Salvati ME: Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol 3:11-25, 2011
17. Lee FY, Camuso A, Castenada S, et al: Preclinical efficacy evaluation of ixabepilone (BMS- 247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 24(suppl 18): 597s, 2006 (abstr 12017)
18. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
19. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518, 2009
20. Iyer RV, Khushalani NI, Tan W, et al: A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) [abstract]. ASCO Gastrointestinal Cancers Symposium, 2010 (abstr 258)
21. Faller BA, Burtness B: Treatment of pancreatic cancer with epidermal growth factor receptortargeted therapy. Biologics 3:419-428, 2009
22. Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al: Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small- cell lung cancer whose tumors have failed first- line platinum-based chemotherapy. J Clin Oncol 25:3448-3455, 2007